Tumor Suppressor Cylindromatosis (CYLD) Controls HIV transcription in an NF-κB-dependent manner

Journal of Virology

Volumn 88, Issue 13, 2014, Pages 7528-7540

  Manganaro, Lara ^a   Pache, Lars ^c   Herrmann, Tobias ^a,d   Marlett, John ^b   Hwang, Young ^f   Murry, Jeffrey ^b   Miorin, Lisa ^a   Ting, Adrian T ^a   König, Renate ^c,e   García Sastre, Adolfo ^a   Bushman, Frederic D ^f   Chanda, Sumit K ^c   Young, John A T ^c   Fernandez Sesma, Ana ^a   Simon, Viviana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c BURNHAM INSTITUTE   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e PAUL EHRLICH INSTITUT   (Germany)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUBIQUITINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN CYLD; UNCLASSIFIED DRUG; CYLD PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JURKAT CELL LINE; LONG TERMINAL REPEAT; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANTAGONISTS AND INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS ACTIVATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, VIRAL; HEK293 CELLS; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; JURKAT CELLS; MACROPHAGES; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84902007691     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00239-14     Document Type: Article

References (80)

1. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, Elledge SJ. 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926. http://dx.doi.org/10.1126/science.1152725.
2. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman FD, Young JA, Chanda SK. 2008. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135:49-60. http://dx.doi.org/10.1016/j.cell.2008 .07.032.
3. Yeung ML, Houzet L, Yedavalli VS, Jeang KT. 2009. A genome-wide short hairpinRNAscreening of Jurkat T-cells for human proteins contributing to productive HIV-1 replication. J. Biol. Chem. 284:19463-19473. http://dx.doi.org/10.1074/jbc.M109.010033.
4. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ, Espeseth AS. 2008. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4:495-504. http://dx.doi.org/10.1016/j.chom.2008.10.004.
5. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S. 2000. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25:160-165. http://dx .doi.org/10.1038/76006.
6. Poblete Gutierrez P, Eggermann T, Holler D, Jugert FK, Beermann T, Grussendorf-Conen EI, Zerres K, Merk HF, Frank J. 2002. Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages. J. Invest. Dermatol. 119:527-531. http://dx.doi.org/10.1046/j.1523-1747 .2002.01839.x.
7. Sun SC. 2010. CYLD: a tumor suppressor deubiquitinase regulating NFkappaB activation and diverse biological processes. Cell Death Differ. 17: 25-34. http://dx.doi.org/10.1038/cdd.2009.43.
8. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796. http://dx.doi.org/10.1038/nature01803.
9. Blake PW, Toro JR. 2009. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum. Mutat. 30:1025-1036. http://dx.doi .org/10.1002/humu.21024.
10. Scheinfeld N, Hu G, Gill M, Austin C, Celebi JT. 2003. Identification of a recurrent mutation in the CYLD gene in Brooke-Spiegler syndrome. Clin. Exp. Dermatol. 28:539-541. http://dx.doi.org/10.1046/j.1365-2230 .2003.01344.x.
11. Zhang G, Huang Y, Yan K, Li W, Fan X, Liang Y, Sun L, Li H, Zhang S, Gao M, Du W, Yang S, Liu J, Zhang X. 2006. Diverse phenotype of Brooke-Spiegler syndrome associated with a nonsense mutation in the CYLD tumor suppressor gene. Exp. Dermatol. 15:966-970. http://dx.doi .org/10.1111/j.1600-0625.2006.00501.x.
12. Ahmed N, Zeng M, Sinha I, Polin L, Wei WZ, Rathinam C, Flavell R, Massoumi R, Venuprasad K. 2011. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 12: 1176-1183. http://dx.doi.org/10.1038/ni.2157.
13. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK. 2007. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28:21-27. http://dx.doi.org/10 .1093/carcin/bgl081.
14. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. 2003. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:801-805. http: //dx.doi.org/10.1038/nature01802.
15. Srokowski CC, Masri J, Hovelmeyer N, Krembel AK, Tertilt C, Strand D, Mahnke K, Massoumi R, Waisman A, Schild H. 2009. Naturally occurring short splice variant of CYLD positively regulates dendritic cell function. Blood 113:5891-5895. http://dx.doi.org/10.1182/blood-2008-08-175489.
16. Harhaj EW, Dixit VM. 2012. Regulation of NF-kappaB by deubiquitinases. Immunol. Rev. 246:107-124. http://dx.doi.org/10.1111/j.1600-065X.2012.01100.x.
17. Moffat JM, Mintern JD, Villadangos JA. 2013. Control of MHC II antigen presentation by ubiquitination. Curr. Opin. Immunol. 25:109-114. http://dx.doi.org/10.1016/j.coi.2012.10.008.
18. Maelfait J, Beyaert R. 2012. Emerging role of ubiquitination in antiviral RIG-I signaling. Microbiol. Mol. Biol. Rev. 76:33-45. http://dx.doi.org/10 .1128/MMBR.05012-11.
19. Lee AJ, Zhou X, Chang M, Hunzeker J, Bonneau RH, Zhou D, Sun SC.2010. Regulation of natural killer T-cell development by deubiquitinase CYLD. EMBO J. 29:1600-1612. http://dx.doi.org/10.1038/emboj.2010.31.
20. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting AT. 2008. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 9:930-936. http://dx.doi .org/10.1038/embor.2008.136.
21. Yoshida H, Jono H, Kai H, Li JD. 2005. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for Toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J. Biol. Chem. 280:41111-41121. http://dx.doi.org/10.1074/jbc.M509526200.
22. Zhang M, Wu X, Lee AJ, Jin W, Chang M, Wright A, Imaizumi T, Sun SC. 2008. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J. Biol. Chem. 283:18621-18626. http://dx.doi.org/10.1074/jbc.M801451200.
23. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NFkappaB. Nature 424:797-801. http://dx.doi.org/10.1038/nature01811.
24. Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF, Leonard TO, Norbury CC, Fitzpatrick L, Zhang M, Sun SC. 2007. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204:1475-1485. http: //dx.doi.org/10.1084/jem.20062694.
25. Thuille N, Wachowicz K, Hermann-Kleiter N, Kaminski S, Fresser F, Lutz-Nicoladoni C, Leitges M, Thome M, Massoumi R, Baier G. 2013. PKCtheta/beta and CYLD are antagonistic partners in the NFkappaB and NFAT transactivation pathways in primary mouse CD3+T lymphocytes. PLoS One 8:e53709. http://dx.doi.org/10.1371/journal.pone.0053709.
26. Koga T, Lim JH, Jono H, Ha UH, Xu H, Ishinaga H, Morino S, Xu X, Yan C, Kai H, Li JD. 2008. Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling. J. Biol. Chem. 283:12546-12554. http://dx.doi.org/10.1074 /jbc.M710518200.
27. Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ. 1989. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature 339:70-73. http://dx.doi.org/10.1038/339070a0.
28. Alcami J, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB, et al. 1995. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in bloodCD4T lymphocytes. EMBO J. 14:1552-1560.
29. Oeckinghaus A, Ghosh S. 2009. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Persp. Biol. 1:a000034. http: //dx.doi.org/10.1101/cshperspect.a000034.
30. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713. http://dx.doi.org/10.1038/326711a0.
31. Bielinska A, Krasnow S, Nabel GJ. 1989. NF-kappa B-mediated activation of the human immunodeficiency virus enhancer: site of transcriptional initiation is independent of the TATA box. J. Virol. 63:4097-4100.
32. Osborn L, Kunkel S, Nabel GJ. 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl. Acad. Sci. U. S. A. 86:2336-2340. http://dx.doi.org/10.1073/pnas.86.7.2336.
33. Zack JA, Kim SG, Vatakis DN. 2013. HIV restriction in quiescent CD4(+) T cells. Retrovirology 10:37. http://dx.doi.org/10.1186/1742-4690-10-37.
34. Korin YD, Zack JA. 1998. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72:3161-3168.
35. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222. http://dx.doi.org/10 .1016/0092-8674(90)90802-L.
36. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. 1990. Hiv-1 replication is controlled at the level of T-cell activation and proviral integration. EMBO J. 9:1551-1560.
37. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, Konig R, Fackler OT, Keppler OT. 2012. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat. Med. 18:1682-1687. http://dx.doi.org/10.1038/nm .2964.
38. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguette N, Benkirane M. 2012. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology 9:87. http://dx.doi.org/10.1186/1742-4690-9-87.
39. Chan JK, Greene WC. 2012. Dynamic roles for NF-kappaB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol. Rev. 246:286-310. http: //dx.doi.org/10.1111/j.1600-065X.2012.01094.x.
40. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal-Rubio D, Shabman RS, Simon V, Rodriguez-Madoz JR, Mulder LC, Barber GN, Fernandez-Sesma A. 2012. DENV inhibits type I IFN production in infected cells by cleavinghumanSTING.PLoSPathog. 8:e1002934. http://dx.doi.org/10.1371/journal.ppat.1002934.
41. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J, Mothes W. 2013. TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J. Virol. 87:257-272. http://dx.doi.org/10.1128/JVI.01804-12.
42. Bosque A, Planelles V. 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+T cells. Blood 113:58-65. http://dx.doi.org/10 .1182/blood-2008-07-168393.
43. Konig R, Chiang CY, Tu BP, Yan SF, DeJesus PD, Romero A, Bergauer T, Orth A, Krueger U, Zhou Y, Chanda SK. 2007. A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4:847-849. http://dx.doi.org/10.1038/nmeth1089.
44. Ooms M, Majdak S, Seibert CW, Harari A, Simon V. 2010. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J. Virol. 84:7961-7969. http://dx.doi.org/10.1128/JVI.00754-10.
45. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944. http://dx.doi.org/10.1006 /viro.1995.1016.
46. Yee JK, Friedmann T, Burns JC. 1994. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 43:99-112. http://dx.doi.org/10.1016/S0091-679X(08)60600-7.
47. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
48. Peden K, Emerman M, Montagnier L. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology. 185:661-672. http://dx.doi.org/10.1016/0042-6822(91)90537-L.
49. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:871-875. http://dx.doi.org/10.1038/nbt0997-871.
50. Harari A, Ooms M, Mulder LC, Simon V. 2009. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83:295-303. http://dx.doi.org/10.1128/JVI.01665-08.
51. Lusic M, Marini B, Ali H, Lucic B, Luzzati R, Giacca M. 2013. Proximity to PML nuclear bodies regulates HIV-1 latency in CD4+T cells. Cell Host Microbe 13:665-677. http://dx.doi.org/10.1016/j.chom.2013.05.006.
52. Butler SL, Hansen MS, Bushman FD. 2001. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:631-634. http://dx.doi.org/10.1038 /87979.
53. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. 2007. The tumor suppressor CYLD regulates entry into mitosis. Proc. Natl. Acad. Sci. U. S. A. 104:8869-8874. http://dx.doi.org/10.1073/pnas .0703268104.
54. Coffin JM, Hughes SH, Varmus H. 1997. Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, NY.
55. Scott ML, Fujita T, Liou HC, Nolan GP, Baltimore D. 1993. The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev. 7:1266-1276. http://dx.doi.org/10.1101/gad.7.7a.1266.
56. Sun SC, Ganchi PA, Ballard DW, Greene WC. 1993. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 259:1912-1915. http://dx.doi.org/10 .1126/science.8096091.
57. Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P, Gevaert K, Beyaert R. 2011. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J. 30:1742-1752. http://dx.doi.org/10.1038/emboj.2011.85.
58. Siliciano RF, Greene WC. 2011. HIV latency. Cold Spring Harb. Persp. Med. 1:a007096. http://dx.doi.org/10.1101/cshperspect.a007096.
59. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868-1877. http://dx.doi.org/10.1093/emboj/cdg188.
60. Van Lint C, Bouchat S, Marcello A. 2013. HIV-1 transcription and latency: an update. Retrovirology 10:67. http://dx.doi.org/10.1186/1742-4690-10-67.
61. Williams SA, Greene WC. 2007. Regulation of HIV-1 latency by T-cell activation. Cytokine 39:63-74. http://dx.doi.org/10.1016/j.cyto.2007.05 .017.
62. Karn J, Stoltzfus CM. 2012. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb. Persp. Med. 2:a006916. http://dx.doi.org/10.1101/cshperspect.a006916.
63. Kao SY, Calman AF, Luciw PA, Peterlin BM. 1987. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-493. http://dx.doi.org/10.1038/330489a0.
64. Sehrawat S, Koenig PA, Kirak O, Schlieker C, Fankhauser M, Ploegh HL. 2013. A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation. Blood 121:1145-1156. http://dx.doi .org/10.1182/blood-2012-08-447409.
65. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. 2009. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J. Biol. Chem. 284:34179-34188. http://dx.doi.org/10.1074 /jbc.M109.046755.
66. Colleran A, Collins PE, O'Carroll C, Ahmed A, Mao X, McManus B, Kiely PA, Burstein E, Carmody RJ. 2013. Deubiquitination of NFkappaB by ubiquitin-specific protease-7 promotes transcription. Proc. Natl. Acad. Sci. U. S. A. 110:618-623. http://dx.doi.org/10.1073/pnas .1208446110.
67. Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC, Sun SC. 2006. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 7:411-417. http://dx.doi.org/10.1038 /ni1315.
68. Tsagaratou A, Trompouki E, Grammenoudi S, Kontoyiannis DL, Mosialos G. 2010. Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner. J. Immunol. 185:2032-2043. http://dx .doi.org/10.4049/jimmunol.0903919.
69. Reissig S, Hovelmeyer N, Weigmann B, Nikolaev A, Kalt B, Wunderlich TF, Hahn M, Neurath MF, Waisman A. 2012. The tumor suppressor CYLD controls the function of murine regulatory T cells. J. Immunol. 189:4770-4776. http://dx.doi.org/10.4049/jimmunol.1201993.
70. Zhao Y, Thornton AM, Kinney MC, Ma CA, Spinner JJ, Fuss IJ, Shevach EM, Jain A. 2011. The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor beta (TGF-beta) signaling and the development of regulatory T cells. J. Biol. Chem. 286:40520-40530. http://dx.doi.org/10.1074/jbc.M111.292961.
71. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, Green DR, Ting AT. 2011. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13:1437-1442. http://dx.doi.org/10.1038 /ncb2362.
72. Liu S, Qiu C, Miao R, Zhou J, Lee A, Liu B, Lester SN, Fu W, Zhu L, Zhang L, Xu J, Fan D, Li K, Fu M, Wang T. 2013. MCPIP1 restricts HIV infection and is rapidly degraded in activated CD4+ T cells. Proc. Natl. Acad. Sci. U. S. A. 110:19083-19088. http://dx.doi.org/10.1073/pnas .1316208110.
73. White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen LA, Kim B, Tuzova M, Diaz-Griffero F. 2013. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe 13:441-451. http://dx.doi.org/10.1016/j.chom.2013.03.005.
74. Cribier A, Descours B, Valadao AL, Laguette N, Benkirane M. 2013. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep. 3:1036-1043. http://dx.doi.org/10.1016 /j.celrep.2013.03.017.
75. Manganaro L, Lusic M, Gutierrez MI, Cereseto A, Del Sal G, Giacca M.2010. Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. Nat. Med. 16:329-333. http://dx.doi.org/10.1038/nm.2102.
76. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O. 2009. Determinants of the establishment of human immunodeficiency virus type 1 latency. J. Virol. 83:3078-3093. http://dx.doi.org /10.1128/JVI.02058-08.
77. Dahabieh MS, Ooms M, Simon V, Sadowski I. 2013. A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J. Virol. 87:4716-4727. http://dx.doi.org/10.1128 /JVI.03478-12.
78. Chan JK, Greene WC. 2011. NF-kappaB/Rel: agonist and antagonist roles in HIV-1 latency. Curr. Opin. HIV AIDS 6:12-18. http://dx.doi.org/10 .1097/COH.0b013e32834124fd.
79. Stroud JC, Oltman A, Han A, Bates DL, Chen L. 2009. Structural basis of HIV-1 activation by NF-kappaB-a higher-order complex of p50:RelA bound to the HIV-1 LTR. J. Mol. Biol. 393:98-112. http://dx.doi.org/10 .1016/j.jmb.2009.08.023.
80. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T.1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/ p300. EMBO J. 17:1087-1095. http://dx.doi.org/10.1093/emboj/17.4 .1087.